IMMATICS NV (IMTX:NASDAQ)
$9.68 -0.28 (-2.8112%)
Analysed IMMATICS NV (IMTX:NASDAQ) News Sources
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
07-05-2026
yahoo.com
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
07-05-2026
yahoo.com
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
07-05-2026
yahoo.com
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
07-05-2026
yahoo.com
Immatics Announces First Quarter 2026 Financial Results and Business Update
12-05-2026
yahoo.com
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
12-05-2026
yahoo.com
Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results
15-05-2026
yahoo.com
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
30-05-2026
yahoo.com
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
31-05-2026
yahoo.com
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
01-06-2026
yahoo.com
What is the current price of IMMATICS NV (IMTX:NASDAQ)?
The current price of IMMATICS NV (IMTX:NASDAQ) is $9.68.
IMMATICS NV (IMTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of IMMATICS NV (IMTX:NASDAQ) since the previous trading day is $-0.28.
IMMATICS NV (IMTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of IMMATICS NV (IMTX:NASDAQ) since the previous trading day is -2.8112%.
What is the most recent average sentiment score for IMMATICS NV (IMTX:NASDAQ)?
The most recent average sentiment score for IMMATICS NV (IMTX:NASDAQ) is 39 out of 100.
What is the most recent average sentiment for IMMATICS NV (IMTX:NASDAQ)?
The most recent sentiment for IMMATICS NV (IMTX:NASDAQ) is .
SEC-8K** Filing Available For IMMATICS NV (IMTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.